Skip to main content
SpringerLink
Log in

Tranexamsäure: der Stellenwert des korrekten Einsatzes und einer individualisierten Risiko-Nutzen-Abwägung

Tranexamic acid: the importance of correct use and individualized risk-benefit analysis

  • Leserbriefe
  • Published:
Der Anaesthesist Aims and scope Submit manuscript

The Original Article was published on 11 June 2021

A Klinische Pharmakologie to this article was published on 23 February 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Blanié A, Bellamy L, Rhayem Y et al (2013) Duration of postoperative fibrinolysis after total hip or knee replacement: a laboratory follow-up study. Thromb Res 131(1):e6–e11. https://doi.org/10.1016/j.thromres.2012.11.006

    Article  CAS  PubMed  Google Scholar 

  2. Borgen PO, Dahl OE, Reikeras O (2013) Biomarkers of coagulation and fibrinolysis during cemented total hip arthroplasty with pre- versus postoperative start of thromboprophylaxis. Thrombosis 2013:563217. https://doi.org/10.1155/2013/563217

    Article  PubMed  PubMed Central  Google Scholar 

  3. Eriksson BI, Hultman E, Martinell S et al (1991) Regional fibrinolysis following total hip replacement. Thromb Res 62(5):441–447. https://doi.org/10.1016/0049-3848(91)90017-Q

    Article  CAS  PubMed  Google Scholar 

  4. Fillingham YA, Ramkumar DB, Jevsevar DS et al (2018) Tranexamic acid use in total joint arthroplasty: the clinical practice guidelines endorsed by the American Association of Hip and Knee Surgeons, American Society of Regional Anesthesia and Pain Medicine, American Academy of Orthopaedic Surgeons, Hip Society, and Knee Society. J Arthroplasty 33(10):3065–3069. https://doi.org/10.1016/j.arth.2018.08.002

    Article  PubMed  Google Scholar 

  5. KDIGO Board Members (2013) KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international supplements, Bd. 3

    Google Scholar 

  6. Pekrul I, Schachtner T, Zwißler B et al (2021) Tranexamsäure zur Blutungsprophylaxe bei Trauma und orthopädischen Eingriffen – Standard oder individualisierte Anwendung? Anaesthesist. https://doi.org/10.1007/s00101-021-00928-5

    Article  PubMed  PubMed Central  Google Scholar 

  7. Pfizer Pharma PFE GmbH (Stand: Mai 2018) Fachinformation „Cyklokapron-Injektionslösung“

  8. Sharrock NE, Go G, Williams-Russo P et al (1997) Comparison of extradural and general anaesthesia on the fibrinolytic response to total knee arthroplasty. Br J Anaesth 79(1):29–34. https://doi.org/10.1093/bja/79.1.29

    Article  CAS  PubMed  Google Scholar 

  9. Taeuber I, Weibel S, Herrmann E et al (2021) Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression. JAMA Surg. https://doi.org/10.1001/jamasurg.2021.0884

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Anaesthesiologie, Abteilung für Transfusionsmedizin, Zelltherapeutika und Hämostaseologie, Universität München (LMU), Marchioninistr. 15, 81377, München, Deutschland

    Isabell Pekrul &  Patrick Möhnle

  2. Anästhesie und Intensivmedizin, Schön Klinik München Harlaching, München, Deutschland

    Thomas Schachtner

  3. Klinik für Anaesthesiologie, Universität München (LMU), München, Deutschland

    Bernhard Zwißler

Authors
  1. Isabell Pekrul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Schachtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bernhard Zwißler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick Möhnle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick Möhnle.

Ethics declarations

Interessenkonflikt

I. Pekrul erhielt Honorare, Forschungsförderung, Reisekosten und Kongressgebühren von den Firmen Bayer AG, Bristol-Myers Squibb, CSL Behring, LFB, Novo Nordisk, Pfizer, Roche, Shire/Takeda und Sobi. P. Möhnle erhielt Honorare, Reisekosten und Kongressgebühren von den Firmen CSL Behring, Pfizer, Biotest, Novo Nordisk, Roche und Shire/Takeda. T. Schachtner und B. Zwißler geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pekrul, I., Schachtner, T., Zwißler, B. et al. Tranexamsäure: der Stellenwert des korrekten Einsatzes und einer individualisierten Risiko-Nutzen-Abwägung. Anaesthesist 70, 616–617 (2021). https://doi.org/10.1007/s00101-021-00990-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00101-021-00990-z

Search

Navigation